Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorKoca, Dogan
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorGumusay, Ozge
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorDayan, Adem
dc.date.accessioned2020-03-26T18:49:44Z
dc.date.available2020-03-26T18:49:44Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractIn this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis. Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis. Patients who only received trastuzumab-based therapy after the development of brain metastases were accepted as the historic control group for survival analyses (n = 65). Patients who received both drugs consecutively or sequentially were excluded from the analyses (n = 34). Median age among 46 patients who received lapatinib plus capecitabine therapy was 45 years (27-76), and median time for development of brain metastases was 11.9 months (0-69 months). Twenty-six out of 38 patients who received lapatinib plus capecitabine and had extracranial metastasis showed partial response or stable diseases (68.4 %). Grade 3-4 toxicity was observed in eight patients (17.3 %). Median overall survival (OS) in patients treated with lapatinib plus capecitabine was significantly increased compared to that in patients treated with trastuzumab-based therapy (19.1 vs. 12 months, respectively, p = 0.039). The incidence of cerebral death was slightly decreased in patients who received lapatinib plus capecitabine compared to those who received trastuzumab-based therapy (32 vs. 43.4 %, p = 0.332). In the multivariate analysis, lapatinib plus capecitabine therapy remained an independent positive predictor for survival [odds ratio (OR), 0.57; p = 0.02]. Although this retrospective multicenter study had several limitations, the results suggest that undergoing lapatinib plus capecitabine therapy after the diagnosis of brain metastasis may further improve survival compared to undergoing only trastuzumab-based therapy.en_US
dc.identifier.doi10.1007/s12282-013-0441-yen_US
dc.identifier.endpage683en_US
dc.identifier.issn1340-6868en_US
dc.identifier.issn1880-4233en_US
dc.identifier.issue6en_US
dc.identifier.pmid23335064en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage677en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s12282-013-0441-y
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30673
dc.identifier.volume21en_US
dc.identifier.wosWOS:000344347700007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGER JAPAN KKen_US
dc.relation.ispartofBREAST CANCERen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectLapatiniben_US
dc.subjectCapecitabineen_US
dc.subjectTrastuzumaben_US
dc.subjectBrain metastasesen_US
dc.subjectBreast canceren_US
dc.subjectHER2en_US
dc.titleClinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncologyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu